Hormonal replacement therapy

Reviews in Endocrine and Metabolic Disorders

Volumn 3, Issue 3, 2002, Pages 243-256

  Sitruk Ware, Regine ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Bone; Breast cancer risk; Cardiovascular risk; Cognition; Endometrial disease; Estrogen; Progestrins

Indexed keywords

ANDROGEN; C 18; CONJUGATED ESTROGEN; DESOGESTREL; DIENOGEST; ELCOMETRINE; ESTRADIOL; ESTROGEN; ESTRONE; ESTRONE SULFATE; GESTAGEN; LEVONORGESTREL; NOMEGESTROL ACETATE; NORETHISTERONE; NORETHISTERONE DERIVATIVE; PROGESTERONE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRIMEGESTONE; TX 525; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BLEEDING; BREAST CARCINOMA; CANCER RISK; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; DRUG ACTIVITY; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; ENDOMETRIUM HYPERPLASIA; ESTROGEN BLOOD LEVEL; HEALTH CARE AVAILABILITY; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; OVARY CARCINOMA; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; RECEPTOR AFFINITY; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SMOKING; SYMPTOM; THROMBOEMBOLISM; UTERUS CARCINOMA;

ESTROGEN REPLACEMENT THERAPY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; PROGESTINS;

EID: 0036744757     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020028510797     Document Type: Review

References (88)

1. Bongaarts J, Zimmer Z. Living arrangements of older adults in the developing world: An analysis of DHS household surveys. J Gerontol Soc Sci 2002;57B:5145-5147.
2. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
3. Colditz GA. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105-1110.
4. Bush TL, Barret-Connor E, Cowan LD, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinic Program follow-up study. Circulation 1987;75:1102-1109.
5. Hulley S, Grady D, Bush T, Furberg C, Herrington O, Riggs B, Vittinghoff E. Heart and estrogen/progestin replacement study (HERS) research group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-613.
6. Herrington DM, Reboussin DM, Bosnihan KB, Sharp PC, Shumaker SA, Snyder TE, Furber CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D. Effects of estrogen replacement on progession of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-529.
7. Mosca L, Collins P. Hormone replacement therapy and cardiovascular disease: A statement for Healthcare professionals from the American Heart Association. Circulation 2001;104:499-503.
8. Mendelsohn ME, Karas RH. Editorial: The time has come to stop letting the HERS tale wag the dogma. Editorial: Circulation 2001;104:2256-2257.
9. Henry D, Robertson J. A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. I. An assessment of the quality of randomized trials published between 1977 and 1995. Climacteric 1998;1:92-111.
10. Groeneveld FP, Bareman FP, Barentsen R, Dokter HJ, Drogendijk AC, Hoes AW. Duration of hormonal replacement therapy in general practice; a follow-up study. Maturitas 1998;29(2):125-131.
11. Yen SSC, Martin PL, Burnier AM, Czekala NM, Greney MO, Jr., Callantine MR. Circulating estradiol, estrone and gonadotropin levels following the administration of orally active 17b-estradiol in postmenopausal women. J Clin Endocrinol Metab 1975;40:518-520.
12. Sitruk-Ware R. Pharmacology of estrogens. Different routes of administration, oral versus transdermal. In: Oettel M, Shillinger E, (eds). Handbook of Experimental Pharmacology, vol 135, Estrogen and Antiestrogens. Heidelberg: Springer Verlag, 1999;247-257.
13. Barnes RD, Lobo RA. Pharmacology of estrogens. In: Mishell DR, Jr., ed. Menopause Physiology and Pharmacology, Chicago Year Book Medical Publishers, 1987;301-315.
14. Gurpide E. Metabolic influences of the action of estrogens; therapeutic implications. Pediatrics 1978;62(Suppl.):1114-1120.
15. Clarck JH, Peck EJ, Jr. Female sex steroids, receptors and function. Monographs on Endocrinology. New York: Springer, 1979.
16. Stanczyk FZ, Shoupe D, Nunez V, Macias-Gonzales P, Vijod MA, Lobo A. A randomized comparison of non-oral estradiol delivery in postmenopausal women. Am J Obstet Gynecol 1988;159:1540-1546.
17. Mishell DR, Jr., Moore DE, Roy S, Brenner PF, Page MA. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and d-norgestrel. Am J Obstet Gynecol 1978;130:55-62.
18. Nash HA, Sanchez-Alvarez F, Mishell DR, Jr., Fraser IS, Maruo T, Harmon TM. Estradiol-delivering vaginal rings for hormone replacement therapy. Am J Obstet Gynecol 1999;181(6):1400-1406.
19. Rigg LA, Hermann H, Yen SSC. Absorption of estrogens from vaginal creams. N Engl J Med 1978;298:195-197.
20. Sitruk-Ware R, De Lignieres B, Basdevant A, Mauvais-Jarvis P. Absorption of percutaneous oestradiol in postmenopausal women. Maturitas 1980;2:207-211.
21. Marty JP, James M, Hajo N, Wepierre J. Percutaneous absorption of oestradiol and progesterone: pharmacokinetic studies. In: Mauvais-Jarvis P, Vickers CFH, Wepierre J, (eds). Percutaneous Absorption of Steroids. London: Academia Press, 1980;205-218.
22. Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17β-estradiol: comparison with conventional oral estrogen used for hormone replacement. Am J Obstet Gynecol 1985;152:1099-1106.
23. Erkkola RU, Hirvonen EI, Juntunen K, Saastamoinen IA, Tuimala RI, Rinne R, Paakkari I. Comparison of transdermal to oral hormone replacement therapy. Eur Menopause J 1995;2:21-27.
24. Reginster JY, Donazzlo Y, Brion N, Lins R. Estradiol pharmaco-kinetics after transdermal application of patches to postmenopausal women: matrix versus reservoir patches. Climacteric 2000;3:168-175.
25. Studd J, Pornel B, Marton I, Bringer J, Varin C, Tsouderos Y, Christiansen C, for the Aerodiol Study Group. Efficacy and acceptability of Intranasal 17β-oestradiol for menopausal symptoms: randomized dose-response study. Lancet 1999;353:1574- 1578.
26. Henzl MR, Edwards JA. Pharmacology of progestins: 17β-hydroxyprogesterone derivatives and progestins of the first and second generation. In: Sitruk-Ware R, Mishell DR, Jr. (eds), Progestins and Antiprogestins in Clinical Practice. New York: Marcel Dekker, 2000;101-132.
27. Sitruk-Ware R. Progestogens in HRT. New molecules. Menopause 2002;9:6-15.
28. Oettel M, Holz C. Hybrid Progestins: the example of Dienogest. In: Sitruk-Ware R, Mishell DR, Jr. (eds), Progestins and Antiprogestins in Clinical Practice. New York: Marcel Dekker, 2000;163-178.
29. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of the new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the Renin-Aldosterone System, body weight, blood pressure, glucose tolerance and lipid metabolism. J Clin Endocrinol Metab 1995;80:1816-1821.
30. Tuba Z, Bardin CW, Dancsi A, Francsics-Czinege E, Molnar C, Csorgei J, Falkay G, Koide SS, Kumar N, Sundaram K, Dukat-Abrok V, Balogh G. Synthesis and biological activity of a new progestogen, 16-methylene-17a-hydroxy-18-methyl-10-norpregn-4ene-3, 20-dione acetate. Steroids 2000;65:266-274.
31. Paris J, Thevenot R, Bonnet P, Granero M. The pharmacological profile of TX 066 (17a-acetoxy-6methyl-19-nor-4, 6-pregna-diene-3, 20-dione) a new oral progestative. Drug Res 1983;33:710-715.
32. Kumar N, Koide SS, Tsong YY, and Sundaram K. Nestorone®: a progestin with a unique pharmacological profile. Steroids 2000;65:629-636.
33. Bullock LP, Bardin CW. Androgenic, synadrogenic and anti-androgenic actions of progestins. Ann NY Acad Sci 1977;286:321-330.
34. Hellman L, Yoshida K, Zumoff B, Levin J, Kream J and Fukushima DK. The effect of medroxyprogesterone acetate on the pituitary-adrenal axis. J Clin Endocrinol Metab 1976;42:912-917.
35. Duc I, Botella J, Bonnet P, Fraboul F, Delansorne R, Paris J. Antiandrogenic properties of nomegestrol acetate. Arzneim Forsch/Drug Res 1995;45(1):70-74.
36. Wilde MI, Balfour JA. Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations. Drugs 1995;50:364-395.
37. Shifren JI, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, Burki RE, Ginsburg ES, Rosen RC, Leiblum SR, Jones KP, Daugherty CA, Caramelli KE, Mazer NA. Transdermal testosterone in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682-688.
38. Kumar N, Didolkar AK, Monder C, Bardin CW, Sundaram K. The biological activity of 7α-Methyl-19-Nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology 1992;130:3677-3683.
39. Pinkerton J, Santen R. Alternatives to the use of estrogen in postmenopausal women. Endocrine Rev 1999;20(3):308-320.
40. Burger HG. Selective oestrogen receptor modulators. Horm Res 2000;53(3):25-29.
41. 1998 Consensus Statement: treatment of estrogen deficiency symptoms in women surviving breast cancer. J Clin Endocrinol Metab 2000;83:1993-2000.
42. Sitruk-Ware R, Thomas JL. Traitement local de l'atrophie urogénitale après la menopause. Praxis 1997;86:1245-1248.
43. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of CEE and medroxyprogesterone acetate. Fertil Steril 2001;75:1065-1075.
44. Notelovitz M, Cassel D, Hille D, Furst KW, Dain MP, Vandepol C, Skarinsky D. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2000;182(1 Pt 1):7-12.
45. Limouzin-Lamothe M, Mairon N, Joyce CRB, Gal ML. Quality of life after the menopause: Influence of hormonal replacement therapy. Am J Obstet Gynecol 1994;170(2):618-624.
46. Wiklund I, Karlberg J, Mattson LA. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol 1993;168:824-830.
47. Burkman RT, Collins JA, Greene RA. Current perspectives on benefits and risks of hormone replacement therapy. Am J Obstet Gynecol 2001;185(2):S13-S23.
48. Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, Judd HL, Caplan RH, Riggs BL. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992;117(1):1-9.
49. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001;285(22):2891-2897.
50. Baron JA, Farahmand BY, Weiderpass E, Michaelsson K, Alberts A, Persson I, Ljunghall S. Cigarette smoking, alcohol consumption, and risk of hip fracture in women. Arch intern Med 2001;161(7):983-988.
51. Jensen J, Christensen C, Rodbro P. Cigarette smoking, serum estrogens, and bone loss during hormone replacement therapy early after menopause. N Engl J Med 1985;313:973-975.
52. Jensen J, Christiansen C. Effects of smoking serum lipoproteins and bone mineral content during postmenopausal hormone replacement therapy. Am J Obstet Gynecol 1988;159:820-825.
53. Carlson LE, Sherwin BB. Higher levels of plasma estradiol and testosterone in healthy elderly men compared with age-matched women may protect aspects of explicit memory. Menopause 2000;7:168-177.
54. Mulnard RA, Cotman CW, Kawas C, Van Dyck CH, Sano M, Doody R. Estrogen replacement therapy for the treatment of mild to moderate Alzheimer disease: A randomized controlled trial. JAMA 2000;283:1007-1015.
55. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340(23):1801-1811.
56. Rich-Edwards JW, Mason JE, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women. N Engl J Med 1995;332:1758-1766.
57. De Cleyn K, Buytaert P, Coppens M. Carbohydrate metabolism during hormonal substitution therapy. Maturitas 1989;11:235-242.
58. Pang SC, Greendale GA, Cedar MI, Cambone AC, Lozano K, Eggena P, Judd HL. Long term effects of transdermal estradiol with and without medroxyprogesterone acetate. Fertil Steril 1993;59:76-82.
59. The writing group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Intervention (PEPI) Trial. JAMA 1995;273:199-208.
60. Ylikorkala O, Cacciatore B, Paakkari I, Tikkanen MJ, Viinikka L, Toivonen J. The long term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane. Fertil Steril 1998;69(5):883-888.
61. Davidson MH, Maki KC, Marx P, Maki AC, Cyrowski MS, Nanavati N, Arce JC. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Arch Intern Med 2000;160(21):3315-3325.
62. Williams JK, Cline JM, Honore EK, Delansome R, Paris J. Coadministration of nomegestrol acetate does not diminish the beneficial effects of estradiol on coronary artery dilator responses in non human primates. Am J Obstet Gynecol 1998;179:1288-1294.
63. Shlipak M, Angeja BG, Go AS, Frederick PD, Canto JG, Grady D, for the National Registry of Myocardial Infarction-3 Investigators. Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. Circulation 2001;104:2300-2304.
64. Perez-Gutthann S, Garcia-Rodriguez LA, Castelsague J, Duque-Oliart A. A population based case-control study. HRT and the risk of venous thromboembolic event. BMJ 1997;314:796-800.
65. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001;285:1460-1465.
66. Coughlin SS, Giustozzi A, Smith SJ, Lee NC. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol 2000;53:367-375.
67. Gray L, Christerpherson W, Hoover R. Estrogens and endometrial carcinoma. J Am Coll Obstet Gynecol 1977;49:385-389.
68. Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Controls 1999;10:253-260.
69. LaVecchia C, Brinton L, McTiernan A. Menopause, hormone replacement therapy and cancer. Maturitas 2001;39:97-115.
70. Janne O, Kauppila A, Kontula K. Female steroid receptors in normal, hyperplastic and carcinomatous endometrium. The relationship to serum steroid hormones and gonadotropins and changes during medoxyprogesterone acetate administration. Int J Cancer 1979;24:545.
71. Woodruff D, Pickar JH. Incidence of endometrial hyperplasia in post-menopausal women taking conjugated estrogens (Premarin) with medroxy progesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994;170:1213-1223.
72. Beresford SAA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349:458-461.
73. Archer D, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol 1994;83:686-692.
74. AinMelk Y. Comparison of two continuous combined estrogen progestogen regimen in postmenopausal women: a randomized trial. Fertil Steril 1996;66:962-968.
75. Odmark IS, Jonsson B, Bäckström T. Bleeding patterns in postmenopausal women using continuous combination hormone replacement therapy with conjugated estrogen and medroxyprogesterone acetate or with 17β-estradiol and norethindrone acetate. Am J Obstet Gynecol 2001;184:1131-1138.
76. Langer RD, Pierce JJ, O'Hanlan KA, Johnson SR, Espeland MA, Trabal JF, Barnabei VM, Merino MJ, Scully RE. The Postmenopausal Estrogen/Progestin Interventions Trial. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. N Engl J Med 1997;337:1792-1798.
77. Collaborative group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-1059.
78. Schairer C, Lubin J, Troisi R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-491.
79. Ross RK, Paganni-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-332.
80. Magnusson C, Baron JA, Correira N. Breast cancer risk following long term oestrogen and oestrogen-progestin replacement therapy. Int J Cancer 1999;31:339-344.
81. Catherino WH, Jeng MH, Jordan VC. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br J Cancer 1993;67:945-952.
82. Catherino WH, Jordan VC. Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. J. Steroid Biochem Mol Biol 1995;55:239-246.
83. Plu-Bureau G, Lê M, Sitruk-Ware, Thalabard JC, Mauvais-Jarvis P. Progestogen use and risk of breast cancer in a cohort study of premenopausal women with benign breast disease. Br J Cancer 1994;70:270-277.
84. Santen R, Pinkerton JV, McCartney C, Petroni GR. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. J Clin Endocrinol Metab 2001;86:16-23.
85. Genazzani AR, Gadducci A, Gambacciani M. Controversial issues in climacteric medicine II: Hormone replacement therapy and cancer. Maturitas 2001;40:117-130.
86. Clinical Synthesis Panel on HRT. Hormonal replacement therapy. Lancet 1999;354:152-155.
87. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, Selzer RH, Liu Cr CR, Liu Ch CH, Azen SP: Estrogen in the prevention of atherosclerosis trial research group. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001 (Dec);135:939-953.
88. The North American Menopause Society. Achieving long-term continuance of menopausal ERT/HRT: Consensus opinion of the North American Menopause Society. Menopause 1998;5:69-76.